trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Allogeneic hematopoietic stem-cell transplantation can exert a therapeutic graft-versus-malignancy effect through nonself immune effector cells contained in the donor stem cell preparation.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Allogeneic hematopoietic stem-cell transplantation can exert a therapeutic graft-versus-malignancy effect through nonself immune effector cells contained in the donor stem cell preparation?

Yes. Allogeneic hematopoietic stem-cell transplantation exerts a well-established graft-versus-malignancy effect mediated by donor immune cells attacking recipient tumor cells.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The claim is a specific, well-established scientific premise in transplant immunology. Multiple provided papers directly discuss or review the graft-versus-leukemia/myeloma effects mediated by donor lymphocytes and cellular therapies following allogeneic stem-cell transplantation, supporting the statement with no papers contradicting it.

Evidence for · 3
Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants
2002
Demonstrates that donor lymphocyte infusions can elicit graft-versus-leukemia effects through immune responses against host cells in transplanted models.
Get citation
Billiau, A. D., Fevery, S., Rutgeerts, O., Landuyt, W., & Waer, M. (2002). Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. doi.org. https://doi.org/10.1182/blood-2002-02-0419

See more details
More for · 2
Adoptive cellular therapy after hematopoietic stem cell transplantation.
2024
Reviews how post-transplant cellular therapies utilizing donor immune cells aim to reduce relapse by targeting malignancies.
Get citation
P, V., P, K., Y, C., CH, J., CM, B., & SO, C. (2024). Adoptive cellular therapy after hematopoietic stem cell transplantation.. doi.org. https://doi.org/10.1002/ajh.27204

Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect
2021
Highlights the graft-versus-myeloma effect driven by donor lymphocyte infusions following allogeneic stem cell transplantation.
Get citation
Gagelmann, N. & Kröger, N. (2021). Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. doi.org. https://doi.org/10.3390/hemato2020012

What does the evidence say?

The claim is a specific, well-established scientific premise in transplant immunology. Multiple provided papers directly discuss or review the graft-versus-leukemia/myeloma effects mediated by donor lymphocytes and cellular therapies following allogeneic stem-cell transplantation, supporting the statement with no papers contradicting it.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work